Skip to main content
Toggle navigation
Search
Home
Post (Tweet)
Yuki Otani (he/him/his)
Eli Lilly and Company
Poster(s):
P4371 - Mirikizumab Pharmacokinetics and Exposure-Response Relationships in Patients With Moderately to Severely Active Crohn’s Disease in Phase 2 and 3 Studies
Tuesday, October 29, 2024
10:30 AM – 4:00 PM
ET
.jpg "Yuki Otani photo")